Kidswell Bio

Kidswell Bio EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Kidswell Bio (4584.T) as of Oct 19, 2026 is -358.72 M JPY. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 116.26 M JPY — a change of -408.55% (lower).

EBITDA

-358.72 MJPY

YoY

-408.55%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Kidswell Bio is 2026 -358.72 M JPY. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Kidswell Bio was 2025 116.26 M JPY. It decreases by -408.55% lower compared to the previous year.

The Kidswell Bio EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2019
-804.48 M JPY
Jan 1, 2020
-7.31 B JPY
Jan 1, 2021
-979.51 M JPY
Jan 1, 2022
-651.14 M JPY
Jan 1, 2023
-618.68 M JPY
Jan 1, 2024
-1.38 B JPY
Jan 1, 2025
116.26 M JPY
Jan 1, 2026
-358.72 M JPY
The Kidswell Bio EBITDA history
YEAREBITDAYoY
-358.72 MJPY-408.55%
116.26 MJPY-108.43%
-1.38 BJPY+122.86%
-618.68 MJPY-4.98%
-651.14 MJPY-33.52%
-979.51 MJPY-86.60%
-7.31 BJPY+808.53%
-804.48 MJPY-11.91%
-913.22 MJPY-25.72%
-1.23 BJPY+49.92%
-820.10 MJPY-0.46%
-823.87 MJPY+60.88%
-512.10 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Kidswell Bio Stock analysis

What does Kidswell Bio do? Kidswell Bio Corp, based in Chuo-Ku, Tokyo, operates in the Health Care sector with a focus on Biotechnology. The company develops biopharmaceutical products, including biosimilars for cancer, renal diseases, and eye conditions, as well as innovative therapies such as anti-RAMP2 antibodies and regenerative medicine using stem cells for pediatric heart diseases and congenital disorders. Listed on 30 November 2012, it employs 41 full-time staff. Kidswell Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Kidswell Bio stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Kidswell Bio is -358.72 M JPY in 2026.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Kidswell Bio changed from 116.26 M JPY to -358.72 M JPY, representing a -408.55% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Kidswell Bio since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Kidswell Bio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Kidswell Bio

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Kidswell Bio